Raise closed, search for fresh raises on Seedstage

Waltham, MA

Advancing bioprinted tissue implants for type 1 diabetes toward human clinical trials.

• Breakthrough research: Demonstrated a functional cure in diabetic mice with bioprinted tissue.
• Strong IP portfolio: 40+ issued and pending patents protect core 3D bioprinting innovations.
• Scalable platform: Designed for minimally invasive, retrievable, and vascularized implants.
• Market potential: Targets a $625B global diabetes cell therapy market.
• Established backing: $14.5M raised to date and collaborations with top pharmaceutical companies.

FluidForm Bio is raising funds to advance the development of its pioneering cell therapy platform targeting type 1 diabetes. The company uses its proprietary FRESH 3D bioprinting technology to produce vascularized pancreatic islet tissue implants designed to generate insulin under the skin, potentially eliminating the need for daily injections. In small animal studies, FluidForm Bio’s approach demonstrated the ability to restore normal blood sugar levels in diabetic models, indicating the potential for long-term insulin independence. The next stage of development includes large animal studies to further validate the technology before pursuing clinical trials.

The broader goal is to create a minimally invasive, retrievable, and scalable implant that could address immune rejection and durability—two major limitations of current experimental treatments. With more than 40 patents issued or pending, the company is building on a strong IP foundation and has already raised $14.5M to date, including $4.5M in 2024. FluidForm Bio’s addressable market is substantial, with internal estimates placing the opportunity for diabetes-related cell replacement therapies at $625 billion globally. The company’s technology has also been leveraged in collaborations with major life sciences firms like Johnson & Johnson, Amgen, and Merck for applications beyond diabetes, reinforcing the potential impact of its 3D bioprinting platform across multiple therapeutic areas.

Company Info

FluidForm Bio uses 3D bioprinting to develop insulin-producing tissue implants for type 1 diabetes treatment.

FluidForm Bio is a biotechnology company pioneering the use of 3D bioprinting to develop therapeutic implants for type 1 diabetes. Its proprietary FRESH (Freeform Reversible Embedding of Suspended Hydrogels) technology enables the creation of vascularized pancreatic tissue designed to produce insulin within the body. The approach focuses on developing structured, functional tissue implants that are minimally invasive, retrievable, and capable of long-term cell survival without systemic immune suppression.

The company has demonstrated proof-of-concept in small animal studies, showing a return to normal blood sugar levels in diabetic mice. It is currently preparing for large animal trials, which represent the next critical step toward future human clinical applications. Backed by over $14.5 million in funding and more than 40 issued and pending patents, FluidForm Bio is targeting a global diabetes cell therapy market estimated at $625 billion. The company’s technology platform has also been validated through research collaborations with major pharmaceutical companies for broader tissue engineering and drug discovery applications.